Skip to main content
Log in

Intranasal Sumatriptan

In Adolescents with Migraine

  • Adis Drug Profile
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

▴ Sumatriptan, a serotonin 5-HT1B/1D agonist, constricts cranial blood vessels and inhibits neuroin-flammatory processes.

▴ A single dose of sumatriptan 10mg (approved European dosage) was significantly more effective than placebo in achieving headache relief at 1 hour post-dose in a well designed study. Headache relief occurred in significantly more adolescents administered a single dose of intranasal sumatriptan 20mg (at 1 and 2 hours) and 5mg (at 2 hours) than placebo (pooled data from two studies).

▴ Sustained headache relief (1–24 and 2–24 hours) occurred in significantly more recipients of a single dose of intranasal sumatriptan 20mg and 5mg than placebo (pooled data from two studies).

▴ Intranasal sumatriptan was generally well tolerated in adolescent migraineurs (in single-episode studies or long term in multiple-episode studies). Taste disturbance occurred more often with intranasal sumatriptan than with placebo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. BMJ 1994 Sep 24; 309: 765–9

    Article  PubMed  CAS  Google Scholar 

  2. Hämäläinen M, Jones M, Loftus J, et al. Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger. Int J Clin Pract 2002 Nov; 56(9): 704–9

    PubMed  Google Scholar 

  3. Perry CM, Markham A. Sumatriptan: an updated review of its use in migraine. Drugs 1998 Jun; 55(6): 889–922

    Article  PubMed  CAS  Google Scholar 

  4. Winner P, Rothner AD, Putnam DG, et al. Demographic and migraine characteristics of adolescents with migraine: Glaxo Wellcome clinical trials’ database. Headache 2003 May; 43(5): 451–7

    Article  PubMed  CAS  Google Scholar 

  5. VanDenBrink AM, van den Broek RWM, de Vries R, et al. Human middle meningeal and coronary artery contraction to eletriptan and sumatriptan [abstract no. III-F1-4]. Cephalalgia 1999 May; 19(4): 398

    Google Scholar 

  6. VanDenBrink AM, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998 Jul 7; 98(1): 25–30

    Article  CAS  Google Scholar 

  7. Moore KHP, Hussey EK, Shaw S, et al. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia 1997 Jun; 17(4): 541–50

    Article  PubMed  CAS  Google Scholar 

  8. Nozaki K, Moskowitz MA, Boccalini P. CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 1992 Jun; 106(2): 409–15

    Article  PubMed  CAS  Google Scholar 

  9. Burstein R. Deconstructing migraine headache into peripheral and central sensitisation. Pain 2001; 89: 107–10

    Article  PubMed  CAS  Google Scholar 

  10. Christensen ML, Mottern RK, Jabbour JT, et al. Pharmacokinetics of sumatriptan nasal spray in adolescents. J Clin Pharmacol 2003 Jul; 43(7): 721–6

    PubMed  CAS  Google Scholar 

  11. Duquesnoy C, Mamet JP, Sumner D, et al. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci 1998 Apr; 6(2): 99–104

    Article  PubMed  CAS  Google Scholar 

  12. Fuseau E, Petricoul O, Moore KHP, et al. Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet 2002; 41(11): 801–11

    Article  PubMed  CAS  Google Scholar 

  13. GlaxoSmithKline (US). Imitrex® (sumatriptan) nasal spray: prescribing information 2004 [online]. Available from URL: http://www.gsk.com [Accessed 2004 Sep 24]

  14. GlaxoSmithKline (UK). Imigran® 10mg and 20mg nasal spray: prescribing information 2003 [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2003 Sep 18]

  15. Evans DC, O’Connor D, Scott-Stevens P, et al. Central sites of action affect the antimigraine efficacy of 5-HT1B/1D receptor agonists [abstract]. Headache Q 2001; 12(1): 45

    Google Scholar 

  16. Moore KHP, McNeal S, Britto MR, et al. The pharmacokinetics of sumatriptan when administered with norethindrone 1 mg/ethinyl estradiol 0.035 mg in healthy volunteers. Clin Ther 2002 Nov; 24(11): 1887–901

    Article  PubMed  CAS  Google Scholar 

  17. Moore KHP, Leese PT, McNeal S, et al. The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. Clin Ther 2002; 24(4): 583–94

    Article  PubMed  CAS  Google Scholar 

  18. Srinivasu P, Rambhau D, Rao BR, et al. Lack of pharmacokinetic interaction between sumatriptan and naproxen. J Clin Pharmacol 2000 Jan; 40(1): 99–104

    Article  PubMed  CAS  Google Scholar 

  19. Scott AK, Walley T, Breckenridge AM, et al. Lack of an interaction between propranolol and sumatriptan. Br J Clin Pharmacol 1991 Nov; 32(5): 581–4

    Article  PubMed  CAS  Google Scholar 

  20. Van Hecken AM, Depré M, De Schepper PJ, et al. Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. Br J Clin Pharmacol 1992 Jul; 34(1): 82–4

    Article  PubMed  Google Scholar 

  21. Fowler PA, Lacey LF, Keene ON, et al. Effect of prophylactic migraine medications on the pharmacokinetic and pharmacodynamic profiles of sumatriptan. Cephalalgia 1991 Jun; 11 Suppl. 11: 228–9

    Article  Google Scholar 

  22. Vachharajani NN, Shyu WC, Nichola PS, et al. A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration. Cephalalgia 2002 May; 22(4): 282–7

    Article  PubMed  CAS  Google Scholar 

  23. Winner P, Rothner D, Webster C, et al. Randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in adolescent migraineurs. Neurology 2004; 62 Suppl. 5: 182

    Google Scholar 

  24. Ahonen K, Hamalainen ML, Rantala H, et al. Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology 2004 Mar 23; 62(6): 883–7

    Article  PubMed  CAS  Google Scholar 

  25. Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 2000 Nov; 106(5): 989–97

    Article  PubMed  CAS  Google Scholar 

  26. Winner P, Rothner AD, Webster C, et al. Overall efficacy of sumatriptan nasal spray in adolescent migraineurs: pooled results from US placebo-controlled trials [abstract]. Plus poster presented at the 46th Annual Scientific Meeting of the American Headache Society 2004 Oct 10–13; Vancouver. Headache 2004; 44(5): 481–2

    Google Scholar 

  27. Rothner AD, Winner P, Nett R, et al. One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study. Clin Ther 2000 Dec; 22(12): 1533–46

    Article  PubMed  CAS  Google Scholar 

  28. Natarajan S, Jabbour JT, Webster CJ, et al. Long-term tolerability of sumatriptan nasal spray in adolescent patients with migraine. Headache 2004; 44: 969–77

    Article  PubMed  Google Scholar 

  29. Woodman R. Glaxo rolls out migraine drug imigran nasal spray for adolescents in Europe 2003 [online]. Available from URL: www.medscape.com [Accessed 2003 Sep 15]

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Monique P. Curran.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Curran, M.P., Evans, H.C. & Wagstaff, A.J. Intranasal Sumatriptan. CNS Drugs 19, 335–343 (2005). https://doi.org/10.2165/00023210-200519040-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200519040-00006

Keywords

Navigation